Arca Biopharma slows losses, R&D expenses in Q2

BOULDER — Arca Biopharma Inc. (Nasdaq: ABIO) saw its losses for the second quarter of 2022 shrink by 33%, to $3.2 million from a $4.8 million net loss in the second quarter of 2021. That’s according to the quarterly report released by the drug manufacturer Wednesday.

Arca also more than halved its research and development expenses year-over-year, to $1.4 million from $3.5 million. 

This comes as the company is exploring a merger or sale of assets; it established a committee to weigh these options amid a 2021 that saw it double its year-over-year losses. 

SPONSORED CONTENT

Empowering communities

Rocky Mountain Health Plans (RMHP), part of the UnitedHealthcare family, has pledged its commitment to uplift these communities through substantial investments in organizations addressing the distinct needs of our communities.

Arca has two drugs in its pipeline: COVID-19 drug candidate rNAPc2 and Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that could be a potential treatment for atrial fibrillation in heart-failure patients.

Arca does not have a timeline for a merger or sale.

The company ended the quarter with $46.4 million in cash and equivalents on hand, enough to sustain its operations through the 2023 fiscal year.